Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3Lymphoid 1

Conditions

Nasopharyngeal Carcinoma 39Carcinoma, Non-Small-Cell Lung 30Carcinoma, Hepatocellular 23Esophageal Squamous Cell Carcinoma 22Triple Negative Breast Neoplasms 19Breast Neoplasms 18Squamous Cell Carcinoma of Head and Neck 17Advanced Solid Tumor 17Melanoma 15Stomach Neoplasms 14Small Cell Lung Carcinoma 13Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 10Carcinoma, Transitional Cell 10Carcinoma, Renal Cell 10Recurrence 9Solid Tumor 7Sarcoma 7Neoplasm Metastasis 7Liver Neoplasms 7Head and Neck Neoplasms 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Advanced Solid Tumors 5Pancreatic Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4

Interventions

Carboplatin 345Cisplatin 240Paclitaxel 208Radiotherapy 206Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 146Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 101Etoposide 98Bevacizumab 96Specimen Handling 84Nivolumab 77durvalumab 73Radiosurgery 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 44Biopsy 43Irinotecan 42Radiation 41Topotecan 39Standard of Care 38Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lung Neoplasms × toripalimab × Clear all
NCT05652712 2022-12-15

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Qianfoshan Hospital

Unknown
200 enrolled
Thoracic

Lung Neoplasms

NCT04731909 2021-02-10

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Third Military Medical University

Phase NA Unknown
80 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02836834 2019-10-22

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Shanghai Junshi Bioscience Co., Ltd.

Phase 1 Unknown
33 enrolled
LymphoidThoracic

Lung Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡